Takeda will lead industry with focus on Oncology

By Eo, Yun-Ho | translator Kim, Jung-Ju

23.02.01 17:41:12

가나다라 0

Looking inside the head of BUDs at multinational pharmaceutical companies- Sun Jin Lee, Head of Oncology BU at Takeda Pharmaceuticals Korea

Understanding patients is of utmost priority in marketing anticancer drugs...identifying data comprehensively also important

Launched Exkivity...provided an oral treatment option for patients with Exon20 insertion mutation

A company has achieved evolution through aggressive investment in line with the current trend. Through such evolution, Takeda Pharmaceuticals has become renowned as a 'Big Pharma' rather than a 'Japanese company' from some point.

The company had previously focused on OTCs and chronic diseases such as diabetes and hypertension. However, through various small and large M&As, the company quickly secured pipelines for anticancer drugs and rare diseases. Until now, the company conducted four M&As, starting with Millennium Pharmaceutical in 2008, Nycomed in 2012, ARIAD Pharmaceuticals in 2017, then Shire in 2018.

As a result, the company has been actively releasing advanced anticancer drugs

Eo, Yun-Ho(unkindfish@dailypharm.com)

If you want to see the full article, please JOIN US (click)